Immunomedics has entered into an exclusive global licence agreement worth up to US$2 B with Seattle Genetics. The latter will develop, fund, manufacture and commercialise IMMU-132, a solid tumour therapy candidate, and will initiate a Phase III trial of IMMU-132 in patients with metastatic triple negative breast cancer and submit an initial BLA to the US FDA for accelerated approval. The agreement included the development of additional indications for IMMU-132 including urothelial cancer, small-cell lung cancer and non-small-cell lung cancer. With declining Adcetris sales, Seattle Genetics is hoping this deal will increase future revenue.